<DOC>
	<DOC>NCT01333592</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.</brief_summary>
	<brief_title>Long-term Study of KAD-1229 in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP4 inhibitor monotherapy Age in the 20 years or over inclusive HbA1c in the range of â‰¥ 6.5 to &lt; 9% Type 1 diabetes mellitus Patients with serious diabetic complications and other serious complications</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Long-term study</keyword>
</DOC>